Innova Captab Limited

INNOVACAP

Sector: PharmaceuticalsSub-sector: CDMO and Branded Generics
Qtr Score Rank 36 / 57 (Top 39 percentile)Growth Score Rank 18 / 51 (Top 67 percentile)

Quarterly Score

Trend: Declining
Concerning decline - Recent 3Q avg 7.17 vs 1Q avg 8.50 (-1.33)

Showing the latest 12 quarterly points (newest to oldest).

Score context (latest 12 quarters)

Q4 FY2025
8.5

Management maintained guidance for the Jammu plant to achieve ₹400 Cr revenue in FY26 (including ~₹30-35 Cr in GST incentives). Long-term guidance is a 25% revenue CAGR over the next 3 years, with existing facilities expected to grow in the 'early teens'.

Quarter summary

  • Commercialization of the Kathua facility in January 2025 marks a strategic shift toward new dosage forms (Penems, LVP, Respules) and provides significant tax/GST incentives.
  • Integration of Sharon Bio-Medicine is yielding results in regulated markets (UK, Canada), with a focus on expanding wallet share among global pharmaceutical clients.

Rationale

  • Strong financial trajectory with FY25 PAT growing 36% YoY to ₹128.3 Cr, significantly outstripping revenue growth of 15%, indicating high operating leverage and reduced finance costs (PAT margins up 160 bps to 10.3%).
  • High growth visibility from the newly commissioned Kathua (Jammu) facility, which contributed ₹36 Cr in its first partial quarter (Q4) and is guided to deliver ₹400 Cr in FY26, representing nearly 32% of current total revenue.
Q1 FY2026
7.5

Management aims for a ₹400 cr annual revenue contribution from the Jammu plant, though they flagged caution on the absolute value due to API price erosion; the operational priority is hitting a ₹100 cr/quarter run-rate at Jammu.

Quarter summary

  • Business reorganization into two streamlined verticals (CDMO and Branded Generics) to integrate Sharon Bio-Medicine and improve strategic clarity.
  • Strategic capacity reallocation: Moving Cephalosporin production from Baddi to Jammu to clear capacity constraints for the international/export market.

Rationale

  • Strong topline execution with 19% YoY revenue growth (₹351.5 cr) achieved despite significant API price deflation of up to 20%, implying robust double-digit volume growth.
  • EBITDA margins expanded 100 bps YoY to 16.1% (₹56.6 cr), driven by a favorable mix shift towards the high-growth Branded Generics segment (+59% YoY) and operational leverage.
Q2 FY2026
5.8

Management maintained a long-term target of doubling the top line every 3-4 years (20%+ CAGR) and sustaining 15% EBITDA margins. However, near-term Jammu facility revenue guidance was cut from INR 400 Cr to ~INR 270-280 Cr for FY26.

Quarter summary

  • Successfully completed international regulatory milestones with UK-MHRA approval for the Baddi Cephalosporin plant and SMDC Ukraine approval for the Jammu facility.
  • The Branded Generics segment is outperforming the core CDMO business, showing 43% H1 growth and acting as a primary driver of the consolidated top line.

Rationale

  • Revenue growth remains healthy at 19.5% YoY for Q2 and H1 FY26, but EBITDA growth of 8% in Q2 significantly lagged top-line growth, indicating margin pressure (EBITDA margin 14.7% vs H1 average of 15.4%).
  • Material structural headwind regarding the Jammu facility's GST incentives: the reimbursement rate dropped from 12% to 5% due to government policy changes. This necessitates a revenue scale-up to INR 1,400 Cr (vs. earlier INR 650 Cr) to achieve the same absolute incentive quantum, diluting near-term margin expectations.
Q3 FY2026Latest
8.2

Management maintains a 20% overall revenue growth target for FY27. For the Jammu facility specifically, FY26 revenue is guided at Rs. 270-280 Cr, with the facility expected to be PAT positive in FY27. Long-term peak revenue potential for Jammu is estimated at Rs. 1,400 Cr+ at 65-75% utilization.

Quarter summary

  • The Jammu facility transition is moving from commissioning to commercial scaling with 14 of 15 key clients already having audited or validated the site.
  • Significant mix shift occurring as Branded Generics (both domestic and international) outpace the core CDMO business, increasing from Rs. 84 Cr to Rs. 151.6 Cr YoY.

Rationale

  • Exceptional revenue growth of 42.3% YoY in Q3 FY26 (Rs. 450.3 Cr) and 27.3% for 9M FY26, driven by a 79% surge in the higher-margin Branded Generics segment.
  • Significant operational ramp-up at the Jammu facility, with revenue increasing 48% sequentially from Rs. 60 Cr in Q2 to Rs. 89 Cr in Q3, nearing EBITDA break-even despite regulatory and GST headwinds.

Future Growth Prospects

Growth score: 8.5Visibility: 80%Updated: 01 Mar 2026, 09:13 am

Catalysts (next 12-24 months)

Total triggers: 3Visible per view: 1 / 2 / 3Slides: 3

Swipe or use arrows to browse all triggers.

capacityFY26E-FY28EImpact: revenueQty: 1400 ₹ Cr

Jamua Facility Revenue Ramp-up

Timeline

  • in progressQ2 FY26 · concall

    Jammu revenue of around Rs. 60 crores previous quarter.

    Guidance revised to ₹270-280 Cr from ₹400 Cr due to API prices and GST cuts.

  • scaledQ3 FY26 · concall

    Achieved a revenue of around Rs. 89 crores from Jammu... nearing the break-even at EBITDA level.

    Revenue grew ~48% QoQ.

Show full timeline (4)
  • in progressFY27E · concall

    Next year, we are very much looking ahead to get a positive contribution from Jammu facility from both EBITDA as well as PAT level.

    Anticipated shift from breakeven to profitability.

  • commissionedJan-2025 · ppt

    Jammu Plant was commercialized in January 2025

Supporting evidence

• Q3 FY26 · concall · Jammu is having a potential to reach around Rs.1,400 crores plus when it will reach an optimum capacity level of 65% to 75%.

regulatoryFY26EImpact: margin

Regulated Market Expansion

Timeline

  • announcedQ2 FY26 · concall

    Successful inspection of our Cephalosporin plant in Baddi by UK-MHRA and Jammu by SMDC Ukraine.

  • commissionedQ3 FY26 · concall

    Bolstered these capabilities with prestigious GMP certification... drive premium opportunities and long-term client loyalty.

    Formal approvals received, enabling exports to UK/Canada/regulated regions.

Supporting evidence

• Q3 FY26 · concall · UK-MHRA approved our cephalosporin Baddi unit and PIC/S via SMDC Ukraine for all our Jammu blocks. These milestones open doors to a regulated, high-growth market.

productH2 FY26Impact: revenue

Panchkula R&D Center Operationalization

Timeline

  • announcedFY25 · ar

    Commenced construction to build an R&D center in Panchkula, Haryana.

  • in progressFY26E · ar

    Expected to be operationalized by H2 FY 2026.

    Advanced stage of development reported.

Supporting evidence

• FY25 · ar · Nearing completion on a new R&D center in Panchkula, Haryana, which will focus on both generic and complex-generic products.

Variant perception

Non-consensus view
Consensus

Market may underappreciate the 19% underlying EBITDA margin ex-Jammu, focusing on the blended 15.8% which is temporarily suppressed by the new plant.

Upside
  • Regulated market entry could double Cephalosporin margins compared to domestic semi-regulated tiers.
Show more (1)
  • Operating leverage from Jammu could lead to a 'plus-plus' margin growth once breakeven is surpassed in FY27.
Downside
  • GST structure changes in Jammu effectively erased a 7% benefit, potentially slowing the payback period of the ₹480 Cr investment.
base case80% conf
Growth: 20

Quick takeaway

Continued 20% volume growth in existing Baddi/Dehradun facilities.

Risk watch: Further delays in Jammu customer on-boarding for regulated blocks.

Show details (2 drivers, 2 risks)

Drivers

  • Continued 20% volume growth in existing Baddi/Dehradun facilities.
  • Jammu facility contribution of ₹270-280 Cr in FY26.

Risks

  • Further delays in Jammu customer on-boarding for regulated blocks.
  • Prolonged API price stagnation suppressing top-line value.
upside case60% conf
Growth: 30

Quick takeaway

Accelerated regulated market exports following UK-MHRA approval.

Risk watch: Regulatory non-compliance in new international geographies.

Show details (2 drivers, 2 risks)

Drivers

  • Accelerated regulated market exports following UK-MHRA approval.
  • Jammu reaching 40%+ utilization ahead of 2-3 year schedule.

Risks

  • Regulatory non-compliance in new international geographies.
  • Competitive intensity in the domestic CDMO market capping price gains.
downside case50% conf
Growth: 10

Quick takeaway

Inventory losses if API prices resume downward correction.

Risk watch: Execution risk in integrating Sharon Bio-Medicine synergistically.

Show details (2 drivers, 2 risks)

Drivers

  • Inventory losses if API prices resume downward correction.
  • GST cut impact on Jammu (7% margin loss) not fully passed to B2B clients.

Risks

  • Execution risk in integrating Sharon Bio-Medicine synergistically.
  • High working capital investment (12-day increase) straining liquidity.

Story of the Stock - Top Strategies

No strategy data available

Business Segments

Community

Share your view anonymously. Comments are public and sorted newest first.

Anonymous post · 1500 characters left

Loading comments...